Comparative Pharmacology
Head-to-head clinical analysis: ATACAND HCT versus HYDRO RX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATACAND HCT versus HYDRO RX.
ATACAND HCT vs HYDRO-RX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ATACAND HCT is a combination of candesartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Candesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor, leading to vasodilation and reduced blood pressure. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, increasing sodium, chloride, and water excretion, thereby reducing plasma volume and blood pressure.
Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption, leading to increased diuresis, decreased plasma volume, and vasodilation. It also reduces peripheral vascular resistance.
One tablet orally once daily. Initial dose: 16 mg candesartan/12.5 mg hydrochlorothiazide. Titrate to maximum 32 mg candesartan/25 mg hydrochlorothiazide once daily.
Initial: 25 mg orally once daily; may increase to 50 mg once daily after 2 weeks based on response. Maximum: 50 mg daily.
None Documented
None Documented
Candesartan: ~9 hours (terminal). Hydrochlorothiazide: 6-15 hours (terminal, mean ~10 hours).
Terminal elimination half-life is 8-12 hours in adults with normal renal function; extended to 20-30 hours in severe renal impairment (CrCl <30 mL/min).
Candesartan: ~33% renal, ~67% biliary/fecal. Hydrochlorothiazide: >95% renal.
Renal excretion of unchanged drug accounts for 60% of elimination; biliary/fecal excretion accounts for 30%; 10% metabolized.
Category C
Category C
Angiotensin II Receptor Blocker / Thiazide Diuretic
Thiazide Diuretic